Evidence map›Paper›PMID 41606227›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

Evaluation of phenyl hydrazide-based compounds as myeloperoxidase inhibitors.

Laryssa C C L Salema, André B Farias, Tiago R Navarro, Patrick P Pimentel, Thuany B S Aguiar, Nelilma C Romeiro, Evanoel C de Lima, Juliana M Raimundo, Leandro L da Silva

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Laryssa C C L SalemaGrupo de Pesquisa em Farmacologia de Produtos Bioativos (FarPBio), Instituto de Ciências Farmacêuticas, Centro Multidisciplinar UFRJ-Macaé, Universidade Federal do Rio de Janeiro, Av. Aluizio da Silva Gomes 50, Macaé, RJ, 27930-560, Brazil.
André B FariasLaboratório Integrado de Computação Científica (LICC), Instituto Multidisciplinar de Química, Centro Multidisciplinar UFRJ-Macaé, Universidade Federal do Rio de Janeiro, Macaé, RJ, Brazil.
Tiago R NavarroLaboratório de Catálise e Síntese de Substâncias Bioativas (LACASB), Instituto Multidisciplinar de Química, Centro Multidisciplinar UFRJ-Macaé, Universidade Federal do Rio de Janeiro, Macaé, RJ, Brazil.
Patrick P PimentelLaboratório de Catálise e Síntese de Substâncias Bioativas (LACASB), Instituto Multidisciplinar de Química, Centro Multidisciplinar UFRJ-Macaé, Universidade Federal do Rio de Janeiro, Macaé, RJ, Brazil.
Thuany B S AguiarLaboratório de Catálise e Síntese de Substâncias Bioativas (LACASB), Instituto Multidisciplinar de Química, Centro Multidisciplinar UFRJ-Macaé, Universidade Federal do Rio de Janeiro, Macaé, RJ, Brazil.
Nelilma C RomeiroLaboratório Integrado de Computação Científica (LICC), Instituto Multidisciplinar de Química, Centro Multidisciplinar UFRJ-Macaé, Universidade Federal do Rio de Janeiro, Macaé, RJ, Brazil.
Evanoel C de LimaLaboratório de Catálise e Síntese de Substâncias Bioativas (LACASB), Instituto Multidisciplinar de Química, Centro Multidisciplinar UFRJ-Macaé, Universidade Federal do Rio de Janeiro, Macaé, RJ, Brazil.
Juliana M RaimundoGrupo de Pesquisa em Farmacologia de Produtos Bioativos (FarPBio), Instituto de Ciências Médicas, Centro Multidisciplinar UFRJ-Macaé, Universidade Federal do Rio de Janeiro, Macaé, RJ, Brazil. julianamontani@gmail.com.
Leandro L da SilvaGrupo de Pesquisa em Farmacologia de Produtos Bioativos (FarPBio), Instituto de Ciências Farmacêuticas, Centro Multidisciplinar UFRJ-Macaé, Universidade Federal do Rio de Janeiro, Av. Aluizio da Silva Gomes 50, Macaé, RJ, 27930-560, Brazil. lelouback@hotmail.com.

Funding

Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/110.998/2013Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/200.940/2023Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/203.664/2021Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro SEI-260003/001219/2020
6 · The paper itself

Abstract

Myeloperoxidase (MPO) has been associated with a broad range of chronic inflammatory diseases since activated MPO catalyzes the production of HOCl, triggering both oxidative stress and inflammation. Since benzohydrazides are known as MPO inhibitors, a series of six N'-phenylbenzohydrazides and one quinazolin-4(3H)-one analogue was evaluated through in vitro assays to measure inhibition of MPO, superoxide dismutase (SOD), and catalase (CAT) activities, as well as DPPH and superoxide-scavenging effects. Pharmacokinetic parameters of the compounds were evaluated in silico, and molecular docking studies were performed to predict their binding modes with the catalytic site of MPO. All phenylbenzohydrazides exhibited potent inhibitory effect on MPO activity, with four of them presenting IC

Indexed as

Enzyme InhibitorsHydrazinesPeroxidasePhenylhydrazinesAnimalsBiphenyl CompoundsCatalaseHumansMolecular Docking SimulationStructure-Activity RelationshipSuperoxide DismutaseSuperoxidesBiphenyl CompoundsCatalaseEnzyme InhibitorsHydrazinesPeroxidasePhenylhydrazinesSuperoxide DismutaseSuperoxidesChronic diseasesHydrazideInflammationOxidative stressPeroxidases

Identifiers

PMID41606227
PMCPMC13152889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.